Market revenue in 2023 | USD 27.0 million |
Market revenue in 2030 | USD 38.0 million |
Growth rate | 5% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.85% in 2023. Horizon Databook has segmented the Argentina pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Constant developments by leading players, such as geographic expansion and new product launches, are expected to contribute to the country’s market growth. For instance, Amoy Diagnostics Co., Ltd. collaborated with Merck KGaA to bring liquid biopsy RAS biomarker tests to Argentina, Mexico, India, and Brazil.
Initially, the test would be made available for research use, only until it gets regulatory authorization from respective countries. In addition, the country has a higher burden of pancreatic cancer, which is expected to propel the demand for the adoption of cancer screening tests.
According to the Global Cancer Observatory, Argentina observed the third largest share (13.6%) of pancreatic cancer cases in 2022 in the Latin America and Caribbean region. Moreover, Latin America has observed a steady rise in the number of oncologists, especially in Brazil & Argentina, as well as awareness of the region’s long-standing scarcity of cancer specialists.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Argentina pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account